AstraZeneca And HUTCHMED’s Savolitinib, In Combination With TAGRISSO, Delivers Significant Survival Benefits In SAFFRON Phase III EGFRm Lung Cancer Trial
First global Phase III trial to show significant progression-free and overall survival benefits in this settingSAFFRON trial results reinforce TAGRISSO as the backbone therapy across EGFRm lung cancerPositive high-level
AstraZeneca's lung cancer medicine worked really well when combined with another drug in a big test, helping patients live longer. When a company shows their medicine works better than expected, it can make people more interested in that company's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.